%0 Journal Article
%T Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
%A Andrew Chan
%A Boris A. Kallmann
%A Jennifer S. Kullmann
%A Klaus Tiel-Wilck
%A Ulrich Engelmann
%J Archive of "Therapeutic Advances in Neurological Disorders".
%D 2019
%R 10.1177/1756286419835077
%X Teriflunomide is a once-daily oral immunomodulatory agent approved for the treatment of relapsing¨Cremitting multiple sclerosis (MS). We aimed to obtain data on the effectiveness, tolerability, and subject satisfaction with teriflunomide (Aubagio£¿) under clinical practice conditions in unselected MS patients
%K multiple sclerosis
%K observational
%K oral
%K patient-related outcomes
%K treatment
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437319/